Carboprost

PreclinicalSmall molecule

SSamuel Lunenfeld Research Institute, Mount Sinai Hospital

Carboprost is one of 56 small molecule programs targeting Cesarean Section. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cesarean SectionActive, not recruiting

Cesarean SectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

83 competitors in Cesarean Section

#DrugCompanyPhaseTrials

Fentanyl-Morphine

SSeoul National University Hospital

Phase 3

2 2

Ondansetron, Dexamethasone

KKing Khaled Eye Specialist Hospital

Phase 3

1 3

Acetaminophen/ibuprofen

SSeoul National University Hospital

Phase 3

1 4

Sebacoyl Dinalbuphine Ester

LLumosa Therapeutics Co., Ltd.

Phase 3

1 5

Morphine - .

RRambam Health Care Campus

Phase 3

1 6

Dynastat

Pfizer

Preclinical

1 7

Proamatine

Takeda

Preclinical

1 8

Duragesic

CCephalon

Preclinical

6 9

Versed

CConrado Roberto Hoffmann Filho

Preclinical

4 10

Catapres

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Carboprost. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carboprost compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carboprost. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Samuel Lunenfeld Research Institute, Mount Sinai Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSamuel Lunenfeld Research Institute, Mount Sinai Hospital

Carboprost

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cesarean Section1 trial

CAR1 trial

Age1 trial

References

Drug Info

Quick Facts

Related News